Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1648 1671 1672
This examiner grants 74% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18363050 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17764509 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18277186 | METHODS AND RELATED ASPECTS FOR DETECTING DISEASES, CONDITIONS, OR DISORDERS IN SUBJECTS USING EXTRACELLUAR VESICLES | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 18338128 | SEQUENCING MICROBIAL CELL-FREE NUCLEIC ACIDS TO DETECT INFLAMMATION, SECONDARY INFECTION, AND DISEASE SEVERITY | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18480009 | USE AND DETECTION METHOD OF FLAVIVIRUS PROTEIN MICROARRAY | Non-Final OA | NATIONAL CHENG KUNG UNIVERSITY |
| 18026943 | PIV5-BASED COVID-19 VACCINE | Final Rejection | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. |
| 18473064 | ORTHOPOXVIRUS SEROLOGY ASSAYS | Non-Final OA | Meso Scale Technologies, LLC. |
| 18286705 | EPSTEIN-BARR VIRUS MRNA VACCINES | Non-Final OA | ModernaTX, Inc. |
| 18282097 | THERAPEUTIC USE OF SARS-COV-2 MRNA DOMAIN VACCINES | Non-Final OA | ModernaTX, Inc. |
| 18284987 | METHODS FOR CHARACTERIZING THE IMMUNE RESPONSE OF A SUBJECT TO A DENGUE VIRUS COMPOSITION | Non-Final OA | TAKEDA VACCINES, INC. |
| 17995158 | Stabilized Vaccine Compositions | Non-Final OA | Janssen Vaccines & Prevention B.V. |
| 18213136 | COVID MULTI-BIOME | Non-Final OA | Microbiota I - Center (Magic) Limited |
| 18258562 | METHOD FOR DETERMINING ACTIVE SARS-COV-2-INFECTIONS | Non-Final OA | CEINGE BIOTECNOLOGIE AVANZATE FRANCO SALVATORE S.C. A R.L. |
| 17991525 | COMPOSITIONS AND DEVICES FOR VACCINE RELEASE AND USES THEREOF | Non-Final OA | VAXESS TECHNOLOGIES, INC. |
| 17920625 | Suprastructure Comprising Modified Influenza Hemagglutinin With Reduced Interaction With Sialic Acid | Non-Final OA | Brian J. Ward |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy